NIKKEI 225
38,329.39 +777.23 (+2.07%) HANG SENG
17,101.85 +272.92 (+1.62%) CRUDE OIL
83.36 0.00 (0.00%) GOLD FUTURES
2,336.30 -5.80 (-0.25%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,476.92 -80.98 (-0.15%)
Coya Therapeutics, Inc. (COYA)
| Previous close | 7.99 |
| Open | 7.92 |
| Bid | 7.86 x 100 |
| Ask | 8.18 x 100 |
| Day's range | 7.90 - 8.45 |
| 52-week range | 3.21 - 10.69 |
| Volume | |
| Avg. volume | 96,753 |
| Market cap | 117.11M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.79 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
- Business Wire
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
HOUSTON, April 22, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer and Chairman of the Board Howard Berman, Ph.D., and Chief Business Development Officer Arun Swaminathan, Ph.D., will participate in the Mizuho Neuroscience Summit being held May 20 – 21 at the Boston Harbor Hotel. Drs. Berman and Swaminathan will also be
- Business Wire
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
HOUSTON, April 18, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.
- Business Wire
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
HOUSTON, April 08, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April
